Birrer, Michael

Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin

Liang, W.-W., Lu, R. J.-H., Jayasinghe, R. G., Foltz, S. M., Porta-Pardo, E., Geffen, Y., Wendl, M. C., Lazcano, R., Kolodziejczak, I., Song, Y., et al. (2023) · Cancer Cell

Epigenetics and DNA MethylationCancer Genomics and Diagnostics

Cited by 105

Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer

Moore, K. N., O'Malley, D. M., Vergote, I., Martin, L. P., Gonzalez-Martin, A., Malek, K., & Birrer, M. J. (2018) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentPARP inhibition in cancer therapy

Cited by 82

Inflammatory Cytokine Tumor Necrosis Factor α Confers Precancerous Phenotype in an Organoid Model of Normal Human Ovarian Surface Epithelial Cells

Kwong, J., Chan, F. L., Wong, K.-K., Birrer, M. J., Archibald, K. M., Balkwill, F. R., Berkowitz, R. S., & Mok, S. C. (2009) · Neoplasia

Ovarian cancer diagnosis and treatmentCancer Risks and Factors

Cited by 62

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer

Krasner, C. N., Campos, S. M., Young, C. L., Chadda, K. R., Lee, H., Birrer, M. J., Horowitz, N. S., Konstantinopoulos, P. A., D'Ascanio, A. M., Matulonis, U. A., et al. (2021) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentCancer therapeutics and mechanisms

Cited by 42

Correlation of Imaging and Plasma Based Biomarkers to Predict Response to Bevacizumab in Epithelial Ovarian Cancer (EOC)

Buechel, M. E., Enserro, D., Burger, R. A., Brady, M. F., Wade, K., Secord, A. A., Nixon, A. B., Mirniaharikandehei, S., Liu, H., Zheng, B., et al. (2021) · Gynecologic Oncology

Ovarian cancer diagnosis and treatmentCancer Risks and Factors

Cited by 17

Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian Cancer

Penson, R. T., Ambrosio, A. J., Whalen, C. A., Krasner, C. N., Konstantinopoulos, P. A., Bradley, C., Matulonis, U. A., & Birrer, M. J. (2023) · The Oncologist

PARP inhibition in cancer therapyOvarian cancer diagnosis and treatment

Cited by 12